Daniel Ketterer, MD
Infectious Disease · Lawrenceville, GANPI 1134393796
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Gilead at 33.6% of the total. Reporting peaked in 2019 at $7,091 and has fallen 83.6% since, to $1,164 in 2024. Among infectious disease clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 345 payments — averaging $44.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
- AbbVie$3K
- Paratek Pharmaceuticals, Inc.$2K
- Viiv Healthcare Company$2K
- Merck$640
- Insmed, Inc.$625
- plus $2K from 17 others
What the payments were for
- Consulting fees$3,14020%
- Speaking & faculty fees$3,12020%
- Travel & lodging$1,80612%
- Food & beverage$7,06046%
- Education$2362%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 41 | $5,158 |
| AbbVie(2 entities) | 33 | $2,973 |
| Paratek Pharmaceuticals, Inc. | 21 | $2,182 |
| Viiv Healthcare Company | 87 | $1,761 |
| Merck | 31 | $640 |
| Insmed, Inc. | 20 | $625 |
| Melinta Therapeutics, LLC | 28 | $467 |
| La Jolla Pharmaceutical Company | 19 | $408 |
| Johnson & Johnson | 27 | $346 |
| Theratechnologies Inc. | 13 | $246 |
| Cumberland Pharmaceuticals, Inc. | 5 | $130 |
| Shionogi Inc | 4 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Mayne Pharma Commercial LLC | 3 | $66 |
| Janssen Scientific Affairs, LLC | 2 | $36 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $27 |
| Octapharma USA, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $17 |
| EMD Serono, Inc. | 1 | $16 |
| Argentum Medical | 1 | $15 |
| Napo Pharmaceuticals Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,362 in reported general payments places this provider in the 90th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 162 | $660,765 |
| JulucaDolutegravir/Rilpivirine | 22 | $82,192 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $53,096 |
| PifeltroDoravirine | 19 | $33,558 |
| Daptomycin | 15 | $20,138 |
| ErtapenemErtapenem Sodium | 20 | $11,101 |
| CeftriaxoneCeftriaxone Sodium | 47 | $3,682 |
| Ampicillin Sodium | 13 | $2,755 |
| Ceftazidime | 12 | $2,171 |
| Vancomycin Hcl | 17 | $1,831 |
| Linezolid | 13 | $1,738 |
| Cefazolin Sodium | 14 | $547 |
| Doxycycline Hyclate | 11 | $319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $5,158 | $660,765162 claims |
| Viiv Healthcare CompanyJuluca | $1,761 | $82,19222 claims |
| MerckPifeltro | $640 | $33,55819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Lawrenceville
- Tzvetan VassilevLawrenceville$9K
- Karuna KusanLawrenceville$7K
- Andrew DoldDacula$1.1M
- Zandraetta Tims-CookAtlanta$848K
- Jeffrey StephensMacon$356K
- Jose VazquezAugusta$335K
- Larry AndersonAtlanta$300K
- Quintin RobinsonAtlanta$270K
- James McMillenAtlanta$177K
- Leandro MenaAtlanta$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.